Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting

Rhea-AI Summary

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced that its preclinical data on Fully Human Albumin Binding candidates (SON-1010, SON-1210, SON-1410) will be presented at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The presentation will showcase an innovative platform for targeted delivery of bispecific interleukins to tumors. The session is scheduled for April 13, 2022, from 9:00 AM to 12:30 PM EDT. The company focuses on developing biologic drugs that improve therapeutic efficiency and safety.

Positive

• Presentation of preclinical data at a major conference can enhance company visibility.
• Development of innovative biologic drugs may attract investor interest.

Negative

• None.

PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from preclinical studies of the company's proprietary Fully Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana.

Details of the abstract and poster presentation are as follows:

Title: An innovative human platform for targeted delivery of bispecific interleukins to tumors
Abstract Number: 4229
Session: Immunology
Presentation Type: Poster
Session Date and Time: Wednesday April 13, 2022; 9:00 AM - 12:30 PM EDT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 9

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as F_HAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's F_HAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. F_HAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the timing of an IND submission, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet Biotherapeutics Investor Contact

Michael V. Morabito, Ph.D.
Solebury Trout
917-936-8430
mmorabito@soleburytrout.com

SOURCE: Sonnet BioTherapeutics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/687932/Sonnet-BioTherapeutics-Announces-Abstract-Accepted-for-Presentation-in-a-Poster-Session-at-the-AACR-2022-Annual-Meeting

FAQ

What is the significance of Sonnet's presentation at the AACR Annual Meeting 2022?

Sonnet's presentation at the AACR Annual Meeting 2022 highlights its proprietary Fully Human Albumin Binding candidates, potentially increasing visibility and interest among investors and researchers.

When is Sonnet BioTherapeutics presenting its research at AACR 2022?

Sonnet BioTherapeutics is scheduled to present on April 13, 2022, from 9:00 AM to 12:30 PM EDT.

What are the Fully Human Albumin Binding candidates developed by Sonnet?

The Fully Human Albumin Binding candidates developed by Sonnet include SON-1010, SON-1210, and SON-1410, aimed at innovative targeted drug delivery.

Where is the AACR Annual Meeting 2022 being held?

The AACR Annual Meeting 2022 is taking place in New Orleans, Louisiana.

What does Sonnet BioTherapeutics focus on?

Sonnet BioTherapeutics focuses on developing biologic drugs, particularly in oncology, utilizing its proprietary F_HAB technology.